Weight Loss Treatment
29,90 €
Weight Loss Treatment29,90 €
Weight Loss TreatmentIf you are overweight and already take a prescription medicine for high blood pressure, type 2 diabetes or cholesterol, any weight management treatment has to fit around what you take now. This page explains what the product information requires, which of your current medicines and conditions the doctor asks about, and what cannot be judged from written answers.
Three of the medicines licensed for weight management in adults act on GLP-1 receptors: semaglutide, tirzepatide (which also acts on GIP receptors) and liraglutide 3 mg. Under section 4.1 of their summaries of product characteristics (SmPC), each may be used by adults whose BMI (body mass index) is 30 kg/m2 or higher, or at least 27 but under 30 kg/m2 together with one or more weight-related conditions, as an addition to a lower-calorie diet and increased physical activity. High blood pressure is named as such a condition for all three, and so is dyslipidaemia, which includes raised cholesterol.
The liraglutide SmPC also sets a point to stop: if, after 12 weeks on the daily 3.0 mg dose, your weight has not fallen by at least 5% from where you started, treatment should end. Which substance, if any, suits you is the doctor's decision after reading your answers.
| Substance | How it is given (SmPC 4.2) | Weight-related conditions named in SmPC 4.1 for a BMI of 27 to under 30 |
|---|---|---|
| Semaglutide | Injection once weekly; a tablet form is taken once daily | Prediabetes or type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease |
| Tirzepatide | Injection once weekly | High blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, type 2 diabetes |
| Liraglutide 3 mg | Injection once daily | Prediabetes or type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea |
All three medicines can cause gastrointestinal side effects such as nausea, vomiting and diarrhoea. Their SmPCs warn that these can lead to dehydration, which can affect kidney function, and they ask you to take precautions to avoid losing fluid.
This matters if you take a blood pressure medicine such as losartan. The losartan SmPC says kidney function can deteriorate with dehydration, and that low blood pressure with symptoms can follow fluid loss through diarrhoea or vomiting; our losartan page explains the checks involved. If you have vomiting or diarrhoea that does not settle while on weight management treatment, contact your GP or a pharmacist about your fluids and your blood pressure tablets.
The liraglutide SmPC also warns about a rise in heart rate and says heart rate should be monitored at regular intervals. Tell a doctor if you notice palpitations or a racing heartbeat at rest.
The semaglutide SmPC says it should not be used as a substitute for insulin and should not be combined with other GLP-1 receptor agonist products; the liraglutide SmPC says the same about combining it with another GLP-1 receptor agonist. If you already take a medicine of this group for diabetes, name it in the questionnaire.
Insulin and sulfonylureas can cause low blood sugar, and the risk rises when a GLP-1 receptor agonist is added. The semaglutide SmPC says it can be lowered by reducing the dose of the sulfonylurea or insulin at the start, so talk to your GP or diabetes team about it first. The semaglutide SmPC also reports a higher risk of complications in diabetic eye disease (retinopathy) and does not recommend it if the retinopathy is uncontrolled or unstable. Metformin is covered on our metformin page.
Because tirzepatide slows the rate at which your stomach empties, tablets and other medicines you swallow may be taken up at a different rate, and this is most noticeable early in treatment. For most oral medicines its SmPC sees no need to adjust the dose; for those with a narrow therapeutic index, warfarin or digoxin for example, it advises monitoring, above all when tirzepatide is started and whenever its dose goes up. The effect should also be considered for medicines that need to work quickly.
Tell the doctor about everything you take, including cholesterol tablets, blood thinners and heart medicines; the long-term blood pressure and cholesterol medicines are described on our heart and blood pressure page. If you are due to have a general anaesthetic or deep sedation, tell the hospital team: the SmPCs of all three report cases of pulmonary aspiration in people taking GLP-1 receptor agonists.
The doctor checks the licensed criteria and anything that rules treatment out. Some situations need a doctor who can see you, or urgent care:
The request starts with a medical questionnaire: you say which medicine you have in mind and tell the doctor what else you take and which conditions you have, including anything for blood pressure, diabetes or cholesterol. Before deciding, the doctor can request your records, test results or a measurement like a blood pressure reading, can suggest an in-person appointment instead, or can turn the request down. There is no video call and no telephone consultation. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. We give no turnaround time.
If the doctor issues a prescription, you receive it as a PDF by email. You print the PDF and take the printout to a pharmacy. A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. This is not an Irish ePrescription and it is not sent through Healthmail.
Weight Loss Treatment costs 29,90 €. The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full. Priority handling (7,90 €) moves your request further up the queue and is no promise about timing.
Our fee covers the doctor's assessment; you pay for the medicine at the pharmacy, at the pharmacy's price. We make no claim about whether a medicine dispensed on this prescription counts towards a medical card or the Drugs Payment Scheme.
There is a single doctor reading these requests, Damian Wojno, a doctor registered in Poland (licence no. 3211301, Regional Medical Chamber in Olsztyn), who also reviewed the medical content of this page. He is not on the register of the Irish Medical Council.
Your blood pressure tablets are not a reason to refuse in themselves: the semaglutide, tirzepatide and liraglutide SmPCs count high blood pressure among the weight-related conditions that apply at a BMI of 27 to under 30, and the doctor will want to know what you take, may ask for a recent reading of your blood pressure and can decline.
The SmPCs give the same two thresholds for semaglutide, tirzepatide and liraglutide: 30 kg/m2 or higher, or 27 to under 30 kg/m2 if you also have at least one weight-related condition, for example prediabetes, type 2 diabetes, high blood pressure or dyslipidaemia.
According to their SmPCs, neither semaglutide nor liraglutide should be used together with a second GLP-1 receptor agonist, so list each diabetes medicine you take when you fill in the questionnaire.
Contact your GP or a pharmacist: the SmPCs warn that vomiting and diarrhoea can lead to dehydration, and the losartan SmPC says fluid loss can cause low blood pressure and affect kidney function.
A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. You print the PDF and take the printout to a pharmacy. Guidance from the Pharmaceutical Society of Ireland says that a prescription shown on a phone would not be considered appropriate.
No. The doctor makes the decision only after reading your answers, and that decision can be to decline, so payment alone does not secure a prescription.